Loading
Sepsis Diagnosis and Treatment · Journal article
American Journal of Perinatology · August 14, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes contemporary evidence on late-onset neonatal sepsis, emphasizing evolving pathogen profiles, diagnostic approaches, and precision therapeutics. It identifies key gaps and research priorities but does not report novel primary data or quantify treatment effects; it serves to summarize the state of clinical knowledge and recommend integrated management strategies for vulnerable preterm and VLBW infants.
Narrative review. Very low birth weight and extremely preterm infants in neonatal intensive care units..
Gram-positive organisms predominate in high-income settings; multidrug-resistant Gram-negative pathogens increasingly reported in low- and middle-income countries with higher morbidity and mortality. Early-life antibiotic exposure and dysbiosis compromise the gut microbiome, further increasing LOS susceptibility. Clinical recognition remains challenging due to nonspecific signs, often leading to delayed or excessive empiric antibiotic therapy.
Source does not report mortality rates, incidence figures, or specific trial results to ground recommendations in hard clinical evidence. Gram-positive organisms predominate in high-income settings; multidrug-resistant Gram-negative pathogens increasingly reported in low- and middle-income countries with higher morbidity and mortality.
Clinicians should recognize LOS as a multifactorial syndrome requiring integration of rapid diagnostics, individualized pharmacokinetic optimization, microbiome-preserving strategies, and context-sensitive infection prevention; this review identifies evidence gaps and priorities for improving outcomes in vulnerable populations.
A narrative review synthesizing contemporary evidence on LOS epidemiology, diagnosis, and management, intended to inform clinical practice and neonatal health policy rather than report a single trial result.
As stated by the source record.
Clinicians should recognize LOS as a multifactorial syndrome requiring integration of rapid diagnostics, individualized pharmacokinetic optimization, microbiome-preserving strategies, and context-sensitive infection prevention; this review identifies evidence gaps and priorities for improving outcomes in vulnerable populations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
OBJECTIVES: Late-onset neonatal sepsis (LOS) remains a major challenge in modern neonatal intensive care units (NICUs), disproportionately affecting very low birth weight (VLBW) and extremely preterm infants. Despite advances in perinatal care, LOS continues to contribute to high mortality, prolonged hospitalization, and long-term neurodevelopmental impairment. Emerging trends-including evolving pathogen profiles, increased antimicrobial resistance (AMR), and widespread microbiome disruption-highlight persistent clinical and public health concerns. This review synthesizes current evidence on the epidemiology, pathophysiology, diagnosis, and management of LOS, with emphasis on evolving diagnostics, antimicrobial stewardship, prevention strategies, and emerging precision approaches. Key gaps and research priorities are highlighted to inform future clinical practice and neonatal health policy. STUDY DESIGN: This narrative review synthesizes contemporary literature, including multicenter cohort studies, national registries, and emerging diagnostic and predictive technologies. RESULTS: LOS arises from the complex interplay between neonatal immune immaturity, invasive NICU interventions, and microbial exposure. Gram-positive organisms predominate in high-income settings, while multidrug-resistant Gram-negative pathogens are increasingly reported in low- and middle-income countries, contributing to higher morbidity and mortality. Early-life antibiotic exposure and dysbiosis compromise the gut microbiome, further increasing susceptibility. Clinical recognition remains challenging due to nonspecific signs, often leading to delayed or excessive empiric antibiotic therapy. Rapid molecular diagnostics, emerging predictive tools, including early-warning models, and serial biomarker monitoring offer opportunities for pathogen-directed therapy, individualized pharmacokinetic optimization, and safe antimicrobial stewardship. Prevention through central-line bundles, human milk feeding, probiotics, strict hand hygiene, and context-specific infection-control strategies remains central to reducing LOS incidence. CONCLUSIONS: LOS represents a multifactorial syndrome with profound implications for survival and neurodevelopment in preterm and VLBW infants. Effective management requires integration of precision diagnostics, individualized therapy, microbiome-preserving strategies, neuroprotective interventions, and equitable implementation of prevention and stewardship programs. Bridging mechanistic understanding with scalable, context-sensitive approaches is critical to improving survival, reducing morbidity, and optimizing long-term outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.